Has Your Portfolio Moved Beyond Genomics Yet?
Advances in chemistry, process engineering, and computing power have led to incredible advances in DNA sequencing and our understanding of the human genome. Much digital ink has been spilled discussing the investing opportunities within the field of genomics, which studies the structure and function of genomes. Genomics has plenty of growth left, but investors need to start considering looking beyond the field of study as 2020 approaches.
Those same technical advances powering genomics have also thrust open new fields of study that were previously off-limits to science or had little application without a fundamental understanding of the genome. These other so-called omics, including transcriptomics, proteomics, fragmentomics, and others. These opportunities are increasingly accessible to individual investors, but it can certainly get a little confusing. Here's a survey of stocks that rely on these omics to keep an eye on at the turn of the next decade.
Source Fool.com
